New HPV approved after international phase 2/3 trial involving Moffitt Cancer Center

A pivotal international phase 2/3 clinical trial involving Moffitt Cancer Center faculty demonstrated that vaccination with Gardasil 9 protects against nine HPV types, seven of which cause most cases of cervical, vulvar, and vaginal disease. The trial data indicate that if populations are vaccinated with Gardasil 9 approximately 90 percent of all cervical cancers worldwide can be prevented. —> Read More Here


Leave a Reply

Your email address will not be published. Required fields are marked *